Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608803 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors
A Phase 1 study of Advanced Cancer, sponsored by Alaunos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT00608803 is a Phase 1 study of Advanced Cancer that has completed, run by Alaunos Therapeutics. The registered enrollment target is 30 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00608803, a Phase 1 study of Advanced Cancer, has completed, sponsored by Alaunos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study of safety of ZIO-201-T in combination with doxorubicin in the treatment of advanced cancer.
Conditions Studied
Interventions
- DRUG ZIO-201-T and doxorubicin
Study Locations (2)
California
- - Santa Monica
Texas
- - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00608803
The ClinicalTrials.gov registry entry for NCT00608803 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Alaunos Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which ZIO-201-T and doxorubicin is the first listed.
NCT00608803 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT00608803 about?
NCT00608803 is a clinical study titled "Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors". The study of safety of ZIO-201-T in combination with doxorubicin in the treatment of advanced cancer.
What is the current status of trial NCT00608803?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-01. Estimated completion is 2009-01.
What conditions does trial NCT00608803 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT00608803?
The interventions under investigation include: ZIO-201-T and doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00608803?
This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00608803 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.